Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (4940)	3/10/1999 6:05:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 5736

Janybird, I have read many posts claiming that Sprx-Bilicheck can not be used one phototherapy started. But I have not seen any reference post it regarding that problem. I have read the studies out by both companies and I post before the references, none said so. I will grant you that one of the Sprx studies was done with all subjects not during phototherapy, then what? there is not scientific why it could not do the job during phototherapy. The skin does not change (unles burning happens and this is extremely rare and will affect both devices). Bilirubin does not change to the point of not being measurable, the only change is from one isomer to the mirror image of the other, from bilirubin to lumirubin. There is not a change in the spectrophotometric characteristics of the compound. Turn the lights off (treatment lights, room lights can stay the same) and Bilicheck works better. If you are right, then CCSI is the winner. Do you think that Respironic will partner Sprx if they will have this big dissadvantage? I strongly doubt that.